Antiendotoxin activity of protegrin analog IB-367 alone or in combination with piperacillin in different animal models of septic shock

Peptides

Volumn 24, Issue 11, 2003, Pages 1747-1752

  Giacometti, Andrea ^a   Cirioni, Oscar ^a   Ghiselli, Roberto ^a   Mocchegiani, Federico ^a   Viticchi, Claudio ^b   Orlando, Fiorenza ^b   D'Amato, Giuseppina ^a   Del Prete, Maria Simona ^a   Kamysz, Wojciech ^c   łLukasiak, Jerzy ^c   Saba, Vittorio ^a   Scalise, Giorgio ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b INRCA   (Italy)

^c MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Antimicrobial peptides; Endotoxin; IB 367; Lipopolysaccharide; Protegrins; Septic shock

Indexed keywords

ANTIINFECTIVE AGENT; PEPTIDE DERIVATIVE; PEPTIDE IB 367; PIPERACILLIN; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMICROBIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ESCHERICHIA COLI; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SEPTIC SHOCK;

ANIMALIA; ESCHERICHIA COLI;

EID: 10744228064     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2003.07.027     Document Type: Article

References (30)

1. Bone R.C. Pathophysiology of sepsis. Ann. Intern. Med. 115:1991;457-469.
2. Bone R.C. Gram-negative sepsis: a dilemma of modern medicine. Clin. Microbiol. Rev. 6:1993;57-68.
3. Brun-Buisson C., Doyan F., Carlet J., Dellamonica P., Gouin F., Lepoutre A.et al. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. JAMA. 274:1995;968-974.
4. Byl B., Clevenbergh P., Kentos A., Jacobs F., Marchant A., Vincent J.L. et al. Ceftazidime- and imipenem-induced endotoxin release during treatment of gram-negative infections. Eur. J. Clin. Microbiol. Infect. Dis. 20:2001;804-807.
5. Castillo M., Toledo-Pereyra L.H., Gutierrez R., Prough D., Shapiro E. Peritonitis after cecal perforation. Am. Surg. 57:1991;313-316.
6. Chen J., Falla T.J., Liu H., Hurst M.A., Fujii C.A., Mosca D.A.et al. Development of protegrins for the treatment and prevention of oral mucositis: structure-activity relationships of synthetic protegrin analogues. Biopolymers. 55:2000;88-98.
7. Cho Y., Turner J.S., Dinh N.N., Leher R.I. Activity of protegrins against yeast-phase Candida albicans. Infect. Immun. 66:1998;2486-2493.
8. Cohen J., McConnell J.S. Antibiotic-induced endotoxin release. Lancet. 2:1985;1069-1070.
9. Colardyn F., Faulkner K.L. Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. Meropenem Serious Infection Study Group. J. Antimicrob. Chemother. 38:1996;523-537.
10. Giacometti A., Cirioni O., Ghiselli R., Viticchi C., Mocchegiani F., Riva A.et al. Effect of mono-dose intraperitoneal cecropins in experimental septic shock. Crit. Care Med. 29:2001;1666-1669.
11. Gough M., Hancock R.E.W., Kelly N.M. Antiendotoxin activity of cationic peptide antimicrobial agents. Infect. Immun. 64:1996;4922-4927.
12. Hancock R.E.W. Therapeutic potential of cationic peptides. Exp. Opin. Invest. Drugs. 7:1998;167-174.
13. Hancock R.E.W., Chapple D.S. Peptide antibiotics. Antimicrob. Agents Chemother. 43:1999;1317-1323.
14. Hancock R.E.W., Scott M.G. The role of antimicrobial peptides in animal defenses. Proc. Natl. Acad. Sci. U.S.A. 97:2000;856-861.
15. Hardaway R.M. A review of septic shock. Am. Surg. 66:2000;22-29.
16. Iwagaki A., Porro M., Pollack M. Influence of synthetic antiendotoxin peptides on lipopolysaccharide (LPS) recognition and LPS-induced proinflammatory cytokine responses by cells expressing membrane-bound CD14. Infect. Immun. 68:2000;1655-1663.
17. Jaccard C., Troillet N., Harbarth S., Zanetti G., Aymon D., Schneider R.et al. Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis. Antimicrob. Agents Chemother. 42:1998;2966-2972.
18. Kamysz W., Kochańska B., Kedzia A., Ochocińska J., Maćkiewicz Z., Kupryszewski G. Statherin SV2 and its analogues. Synthesis and evaluation of antimicrobial activity. Polish J. Chem. 76:2002;801-806.
19. Manocha S., Feinstein D., Kumar A., Kumar A. Novel therapies for sepsis: antiendotoxin therapies. Exp. Opin. Invest. Drugs. 11:2002;1795-1812.
20. Mira J.P., Cariou A., Grall F., Delclaux C., Losser M.R., Heshmati F.et al. Association of TNF2, a TNFα promoter polymorphism, with septic shock susceptibility and mortality. JAMA. 282:1999;561-568.
21. Mosca D.A., Hurst M.A., So W., Viajar B.S.C., Fujii C.A., Falla T.J. IB-367, a protegrin peptide with in vitro and in vivo activities against the microflora associated with oral mucositis. Antimicrob. Agents Chemother. 44:2000;1803-1808.
22. National Committee for Clinical Laboratory Standards: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 5th ed. Approved Standard. M7-A5. National Committee for Clinical Laboratory Standards, Wayne, PA, 2001.
23. Parker S.J., Watkins P.E. Experimental models of gram-negative sepsis. Br. J. Surg. 88:2000;22-30.
24. Prins J.M., Kuijper E.J., Mevissen M.L.C.M., Speelman P., van Deventer S.J.H. Release of tumor necrosis factor alpha and interleukin 6 during antibiotic killing of Escherichia coli in whole blood: influence of antibiotic class, antibiotic concentration, and presence of septic serum. Infect. Immun. 63:1995;2236-2242.
25. Saklayen M.G. CAPD peritonitis: incidence, pathogens, diagnosis, and management. Med. Clin. N. Am. 74:1990;997-1010.
26. Scott M.G., Yan H., Hancock R.E.W. Biological properties of structurally related (helical cationic antimicrobial peptides. Infect. Immun. 67:1999;2005-2009.
27. Sharma V.K., Dellinger R.P. Recent developments in the treatment of sepsis. Exp. Opin. Invest. Drugs. 12:2003;139-152.
28. Yethon J.A., Whitfield C. Lipopolysaccharide as a target for the development of novel therapeutics in gram-negative bacteria. Curr. Drug Targets Infect. Disord. 1:2001;91-106.
29. Wheeler A.P., Bernard G.R. Treating patients with severe sepsis. N. Engl. J. Med. 340:1999;207-214.
30. Zervos E., Norman J., Denham D., Carey L.C., Livingstone D., Rosemurgy A.S. Cytokine activation through sublethal hemmorhage is protective against early lethal endotoxic challenge. Arch Surg. 132:1997;1216-1221.